Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,118,555.02 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 100,713 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $90.54, for a total value of $9,118,555.02. Following the completion of the sale, the executive vice president owned 29,276 shares of the company’s stock, valued at $2,650,649.04. This represents a 77.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.03, for a total value of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total value of $1,605,085.44.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total value of $230,848.54.

Dianthus Therapeutics Trading Up 3.6%

Shares of DNTH stock traded up $3.18 on Thursday, reaching $92.48. The company had a trading volume of 921,016 shares, compared to its average volume of 931,449. The stock has a market cap of $5.21 billion, a PE ratio of -23.18 and a beta of 1.47. The company has a 50-day moving average of $89.05 and a 200-day moving average of $86.15. Dianthus Therapeutics, Inc. has a 12 month low of $34.29 and a 12 month high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.94) by $0.13. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. Sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DNTH has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Roth Capital initiated coverage on Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a “buy” rating and a $113.00 price objective on the stock. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a report on Friday, September 11th. They set an “overweight” rating and a $135.00 target price on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $134.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, November 5th. Finally, Truist Financial boosted their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $128.77.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. ABS Investment Management LLC bought a new position in Dianthus Therapeutics during the 2nd quarter worth about $194,960,000. EFG International AG bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $49,000. GAMMA Investing LLC boosted its position in shares of Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after buying an additional 254 shares during the period. Fifth Third Bancorp boosted its position in shares of Dianthus Therapeutics by 23.6% during the third quarter. Fifth Third Bancorp now owns 676 shares of the company’s stock worth $60,000 after buying an additional 129 shares during the period. Finally, Global Retirement Partners LLC bought a new position in shares of Dianthus Therapeutics during the second quarter worth about $93,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.